A
Apiject
A public-benefit medical technology company working to use the platform to bring more prefilled, single-dose injections to patients everywhere
About Apiject
ApiJect is a technology and innovation company that operates in the pharmaceutical industry, specifically in the area of drug delivery systems. The company's primary focus is on improving the fill-finish process of injectable medicines, a critical step in the production of pharmaceuticals where the drug is filled into its final container. ApiJect's technology combines Blow-Fill-Seal (BFS) aseptic drug packaging with connectable components to create high-quality, prefilled drug delivery systems. BFS is a method used to manufacture sterile, liquid pharmaceutical products that are packaged in a sealed container.
ApiJect's clients are pharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) around the world. The company assists these clients in creating scalable, cost-efficient drug delivery systems and supports them in manufacturing these devices at their own facilities or a trusted contract manufacturer.
The company's business model is based on licensing its technology to these pharmaceutical companies and CDMOs. This includes drug-specific BFS mold and device design licensing, device design and development, prototype development, and BFS production support.
ApiJect has been recognized for its innovative approach, with its Prefilled Single-Dose Injector being a finalist in the prestigious CPHI Pharma Awards 2023 in the Drug Delivery & Device category. The company's engineers have also made advances in temperature management methods that could potentially enable the fill-finish of many temperature-sensitive biologics and vaccines.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Stamford, United States
- Employees
- 54
- Open positions
- None listed
- Dealroom signal
- 63.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Tech for Biotech and Pharma, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Oct 2024 | $425K | — | Bill & Melinda Gates Foundation | ↗ |
| DEBTDebt | Aug 2024 | $35M | — | Trinity Capital | ↗ |
Growth signals
Latest recorded traffic for Apiject is 3.8K monthly website visits, up 171.4% over the last three months. Apiject's team declined 3.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Bill & Melinda Gates Foundation
Series B and later3 investors entered at this stage
Royalty Pharma
Jefferies Group
Trinity Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Apiject on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Apiject’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.